Table 1.
Prognostic impact of ABC transporters in 25 patients with Ewing sarcoma. Associations with prognosis were calculated by univariate analysis using the log-rank (Mantel-Cox) test
| Relapse-Free Survivala | Overall Survivalb | ||||
|---|---|---|---|---|---|
| Gene | n | Events (% RFS) | p-Univariate | Events (% OS) | p-Univariate |
| ABCA2 | 0.067 | 0.103 | |||
| Low | 13 | 10 (17.9%) | 8 (34.6%) | ||
| High | 12 | 6 (50.0%) | 4 (66.7%) | ||
| ABCA6 | 0.026 | 0.085 | |||
| Low | 12 | 9 (20.8%) | 7 (38.1%) | ||
| High | 13 | 7 (46.2%) | 5 (61.5%) | ||
| ABCA7 | 0.035 | 0.023 | |||
| Low | 13 | 11 (8.8%) | 9 (26.0%) | ||
| High | 12 | 5 (58.3%) | 3 (75.0%) | ||
| ABCB1 | 0.530 | 0.215 | |||
| Low | 12 | 8 (29.2%) | 7 (37.5%) | ||
| High | 13 | 8 (38.5%) | 5 (61.5%) | ||
| ABCB10 | 0.951 | 0.563 | |||
| Low | 12 | 8 (28.1%) | 5 (55.6%) | ||
| High | 13 | 8 (38.5%) | 7 (46.2%) | ||
| ABCC1 | 0.468 | 0.965 | |||
| Low | 12 | 9 (18.7%) | 6 (46.3%) | ||
| High | 13 | 7 (46.2%) | 6 (53.8%) | ||
| ABCC2 | 0.967 | 0.859 | |||
| Low | 12 | 8 (28.1%) | 6 (46.3%) | ||
| High | 13 | 8 (38.5%) | 6 (53.8%) | ||
| ABCC4 | 0.055 | 0.055 | |||
| Low | 12 | 10 (9.7%) | 8 (28.1%) | ||
| High | 13 | 6 (53.8%) | 4 (69.2%) | ||
| ABCC5 | 0.080 | 0.361 | |||
| Low | 12 | 10 (9.5%) | 7 (37.5%) | ||
| High | 13 | 6 (53.8%) | 5 (61.5%) | ||
| ABCC11 | 0.172 | 0.535 | |||
| Low | 12 | 6 (46.9%) | 5 (55.6%) | ||
| High | 13 | 10 (23.1%) | 7 (46.2%) | ||
| ABCE1 | 0.142 | 0.446 | |||
| Low | 13 | 10 (17.6%) | 7 (42.7%) | ||
| High | 12 | 6 (50.0%) | 5 (58.3%) | ||
| ABCF1 | 0.065 | 0.348 | |||
| Low | 12 | 10 (9.5%) | 7 (37.5%) | ||
| High | 13 | 6 (53.8%) | 5 (61.5%) | ||
| ABCF2 | 0.329 | 0.837 | |||
| Low | 12 | 9 (19.0%) | 6 (46.3%) | ||
| High | 13 | 7 (46.2%) | 6 (53.8%) | ||
| ABCF3 | 0.123 | 0.212 | |||
| Low | 12 | 9 (19.4%) | 7 (38.1%) | ||
| High | 13 | 7 (46.2%) | 5 (61.5%) | ||
| ABCG2 | 0.284 | 0.498 | |||
| Low | 12 | 8 (30.0%) | 6 (47.6%) | ||
| High | 13 | 8 (38.5%) | 6 (53.8%) | ||
Results in bold are significant at p < 0.05. aRFS, relapse-free survival (median follow-up: 21 months; range 4–328 months); bOS, overall survival (median follow-up: 72 months; range 10–328 months)